Through the addition, exchange or depletion of anti-E3–anti-CD33 or anti-E3–anti-CD123-targeting molecules we could show modularity by sequentially redirecting SAR T cells toward different AML targets (Fig. 3C and Supplementary Fig. 3A). Here, CD33 is linked to acute myeloid leukemia.